We are a clinical stage biopharmaceutical company leveraging our two proprietary technology platforms to discover, design and develop novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases associated with protein misfolding. We execute a clear strategy around the three pillars of Alzheimer's disease, other significant and NeuroOrphan indications and diagnosis.
Our two proprietary technology platforms allow us to discover, design and develop antibodies, small molecules and vaccines. These platforms are the engines for our diverse pipeline of product candidates, which currently consists of nine therapeutic product candidates and three diagnostic product candidates with six currently in clinical trials.
We believe that our multiple strategic alliances with leading industry partners like Genentech, Janssen Pharmaceuticals, Life Molecular Imaging and Eli Lilly and Company provide external validation of our Company and the quality of our science.
Our Investor Center is designed to provide you with convenient access to information about our Company.
Data Provided by Refinitiv. Minimum 15 minutes delayed.